Skip to Main Content

Paper Details

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
10
2023
BRAF, BRAF locus, BRAF mutations, BRAFV600E, BRAFV600E mutation, BRAFV600E-mutated multiple myeloma, MEK, Myeloma, Patients, RAS, RRMM, binimetinib, encorafenib, multiple myeloma, patients, relapsed/refractory multiple myeloma
Author NameAffiliation
Cyrus KhandanpourUniversity Hospital Munster
Cyrus KhandanpourUniversity Medical Center Schleswig-Holstein Campus Lubeck, University of Lubeck
Albrecht StenzingerInstitute of Pathology, Heidelberg University Hospital
Niels WeinholdHeidelberg University Hospital
  • 1 - 4

Datasets

Release 1.2